Cystic fibrosis and Crohn's disease treated successfully with infliximab

Apr 19, 2010

A research team from Italy reported a case of a 23-year-old patient suffering from cystic fibrosis (CF) and Crohn's disease who was successfully treated with infliximab. This case report was thought to be one of the first regarding the use of biological therapy in patients with CF.

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene ( transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

Pulmonary complications are the most common causes of mortality, but the presenting symptoms are very often linked to gastrointestinal and pancreatic biliary diseases. These are mainly caused by the unusual viscosity of the secretions in hollow organs and in the ducts of solid organs. Crohn's dis¬ease (CD) is a chronic which may be localized throughout the . The association between CD and CF is known; there are reports of a prevalence of CD in patients suffering from CF 17 times higher than in controls.

A research article to be published on April 21, 2010 in the addresses this question. A research team led by Professor Gian Luigi de' Angelis, reported the first case of a patient with CF and CD treated with .

After initiation of infliximab in this patient, there was an improvement of colonic lesions and general condition without any infective complication and particularly without any decline of lung function.

This report confirms the preliminary data regarding the possibility that airway inflammation in CF plays a crucial role in lung damage and that the inflammation is mediated by alpha. Therefore, the use of anti-tumor necrosis factor alpha antibody improved CD and did not generate any complications of lung function, perhaps promoting an anti-inflammatory effect both on colon and lung.

Explore further: Health officials warn of Sea-Tac measles exposure

More information: Vincenzi F, Bizzarri B, Ghiselli A, de' Angelis N, Fornaroli F, de' Angelis GL. Cystic fibrosis and Crohn's disease: Successful treatment and long term remission with infliximab. World J Gastroenterol 2010; 16(15): 1924-1927. www.wjgnet.com/1007-9327/full/v16/i15/1924.htm

add to favorites email to friend print save as pdf

Related Stories

Mucous breakthrough in mice holds promise for cystic fibrosis

Jul 29, 2008

A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice. This discovery by Dr. Richard Rozmahel, a scientist with the Lawson ...

New drug hope for cystic fibrosis patients

Sep 09, 2008

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol will tell an audience at the BA Festival ...

Recommended for you

Fourth Sierra Leonean doctor dies from Ebola

15 hours ago

A fourth Sierra Leonean doctor, a woman, died Sunday after contracting the dreaded Ebola virus, a top health official said, while a Dutch charity repatriated two doctors suspected of having been contaminated ...

Dutch Ebola doctors 'to be evacuated on Sunday'

18 hours ago

Two Dutch doctors feared to have contracted the deadly Ebola virus while working in Sierra Leone are set to be flown back to the Netherlands "as soon as possible", the foreign ministry said Saturday.

Glycemic control linked to lumbar surgery complications

Sep 12, 2014

(HealthDay)—For patients with diabetes mellitus (DM) undergoing degenerative lumbar spine surgery, suboptimal glycemic control contributes to increased risk of complications and poor outcomes, according ...

User comments : 0